A Multicenter, Open- Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis Save

Date Added
January 8th, 2019
PRO Number
Pro00077585
Researcher
Lara Wine lee

List of Studies

Silhouette
Keywords
Skin
Summary

This study is to treat patients with moderate to severe atopic dermatitis for whom topical treatments have not been effective. This study will evaluate the safety and efficacy of systemic treatment with baricitinib.

Participation in the study will take about 12 visits over a period of about 108 weeks.

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-6690
powab@musc.edu

Protocol I4V-MC-JAIW. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis Save

Date Added
February 27th, 2018
PRO Number
Pro00075349
Researcher
Lara Wine lee

List of Studies

Silhouette
Keywords
Skin
Summary

This study is to treat patients with moderate to severe atopic dermatitis for whom topical treatments have not been effective. This study will evaluate the safety and efficacy of systemic treatment with baricitinib.
Participation in the study will take about 16 visits over a period of about 26 months.

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-7333
vazquezo@musc.edu

A Phase 3, Randomized, Multicenter, Single-blind Controlled Study evaluating Arteriovenous fistula outcomes with and without a Perivascular Sirolimus-eluting collagen Implant (The ACCESS Trial) Save

Date Added
April 15th, 2016
PRO Number
Pro00048577
Researcher
Thomas Powell

List of Studies

Keywords
Kidney, Surgery
Summary

Subjects of either gender, who are at least 18 years of age, undergoing hemodialysis or those expected to start dialysis within 6 months, and require a new single-stage radiocephalic or brachiocephalic end-to-side fistula will be eligible to participate in this study. Subjects who meet eligibility criteria and undergo successful AV fistula creation (i.e., a patent fistula confirmed by the presence of a thrill and bruit with satisfactory hemostasis) will be eligible for enrollment. The number of planned patients enrollment is 240, with approximately 220 subjects planned to be randomized in equal proportions to treatment and control to yield approximately 200 evaluable subjects. Evaluations to determine fistula suitability for cannulation will start no earlier than day 28 post index procedure and will continue to least weekly. All enrolled subjects will be followed for a period of one year from the time of their index procedure.

Institution
Palmetto
Recruitment Contact
Michelle Hardin
803-252-9907 ext 247
mhardin@columbianephrology.com

Change_preferences

-- OR --

Create_login